Nasal Allergy
Conditions
Keywords
allergic rhinitis, Budesonide, luticasone propionate
Brief summary
Budesonide is a medication of the corticosteroid type. Available as an inhaler, nebulization solution, The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease is used for allergic rhinitis and nasal polyps fluticasone propionate
Detailed description
The current study aims to compare between results of budesonid nasal irrigation and fluticasone nasal spray in the treatment of adult patients with Allergic Rhinitis.
Interventions
DRUGBudesonide buffered with 0.9% isotonic saline.
120 patients received budesonide buffered with 0.9% isotonic saline.
DRUGFluticasone propionate nasal spray.
120 patients received fluticasone propionate nasal spray.
OTHER0.9% saline for nasal irrigation.
120 patients used 0.9% saline for nasal irrigation.
Sponsors
Benha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Adult age between 18 and 60 years old. * Patients with allergic rhinitis evidence by past skin prick testing. Patients were given a skin prick test with a panel of dog, cat, Dermatophagoides farinae, D pteronyssinus, Alternaria, Penicillium, Hormodendron, Aspergillus, grass pollen mix, tree pollen mix, and ragweed allergen extracts (100,000 Allergen Unit/mL). Histamine, 10 mg/mL, was used as a positive control, and the diluent was used as the negative control. A positive reaction was defined as a wheal diameter at least 3 mm greater than the diluent control and/or at least a 50-mm flare (ie, erythema measured as the sum of the greatest diameter and the perpendicular diameter through the midpoint of the greatest diameter)
Exclusion criteria
* Patients who had autoimmune diseases or any immune compromised diseases including diabetes, chemotherapy. * Patients with a history of nasal surgery. * Patients who received systemic or topical corticosteroids, herbal drugs, beta blocking agent within the previous month of enrolment. * Patients with asthma and COPD, nasal bleeding, obstructing nasal polyps, paranasal sinus.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement | 1 month | improvement measured by pre- and post-treatment SNOT score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Endoscopic examination improvement | 1 month | by comparing pre and post treatment lund\*Mackay score |
Other
| Measure | Time frame | Description |
|---|---|---|
| Effects on serum cortisol level | 1 month | Monitoring of pre and post treatment measurements of e morning serum cortisol level |
Countries
Egypt
Outcome results
None listed